Abstract | OBJECTIVES: BACKGROUND: METHODS: Anesthetized rats were subjected to left coronary artery ligation for 60 min (n = 10, ischemia group), or ischemia followed by 60 min of reperfusion ( n = 30, ischemia-reperfusion group). Rats in the latter group were treated with saline, the LOX-1 blocking antibody JXT21 (10 mg/kg), or nonspecific anti-goat immunoglobulin G ( IgG) (10 mg/kg). Ten other rats underwent thoracotomy without coronary ligation ( sham control). RESULTS:
Ischemia-reperfusion was associated with an increase in LOX-1 expression, lipid peroxidation and apoptosis, a large infarct area, and a decrease in left ventricular function (all, p < 0.01 vs. sham control and ischemia alone groups). Treatment of rats with LOX-1 antibody prevented ischemia-reperfusion-induced upregulation of LOX-1. Importantly, the LOX-1 antibody reduced apoptosis by 48%, lipid peroxidation by 39%, and myocardial infarct size by 45%, and improved left ventricular function (first derivative of pressure measured over time: -47% to -18%, p < 0.01). Nonspecific IgG had no effect. CONCLUSIONS:
|
Authors | Dayuan Li, Victor Williams, Ling Liu, Hongjiang Chen, Tatsuya Sawamura, Francesco Romeo, Jawahar L Mehta |
Journal | Journal of the American College of Cardiology
(J Am Coll Cardiol)
Vol. 41
Issue 6
Pg. 1048-55
(Mar 19 2003)
ISSN: 0735-1097 [Print] United States |
PMID | 12651056
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
- OLR1 protein, rat
- Olr1 protein, mouse
- Receptors, LDL
- Receptors, Oxidized LDL
- Scavenger Receptors, Class E
|
Topics |
- Animals
- Apoptosis
(genetics, physiology)
- Disease Models, Animal
- Gene Expression
(genetics, physiology)
- Male
- Mice
- Mice, Inbred BALB C
- Necrosis
- Rats
- Rats, Sprague-Dawley
- Receptors, LDL
(genetics, physiology)
- Receptors, Oxidized LDL
- Reperfusion Injury
(genetics, pathology, physiopathology)
- Scavenger Receptors, Class E
- Ventricular Dysfunction, Left
(genetics, pathology, physiopathology)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|